1. How to measure homologous recombination deficiency in ovarian cancer
- Author
-
Iain A. McNeish and Claudia Marchetti
- Subjects
Genetics ,endocrine system diseases ,biology ,DNA repair ,Somatic cell ,Poly ADP ribose polymerase ,General Engineering ,medicine.disease ,female genital diseases and pregnancy complications ,Germline ,Serous fluid ,biology.protein ,medicine ,Cancer research ,Homologous recombination ,Ovarian cancer ,Polymerase - Abstract
Defective DNA repair via homologous recombination (HR) is common in ovarian high grade serous carcinomas, and homologous recombination deficiency (HRD) represents an important therapeutic target in epithelial ovarian cancers (EOCs). The development of poly(ADP ribose) polymerase (PARP) inhibitors (PARPi) has been an important advance in the treatment of HR-deficient EOCs with the potential to change daily clinical practice. However, while germline and somatic mutations in BRCA1 and BRCA2 are still the most important mechanisms of HRD, alterations in other DNA repair pathways might also contribute to defective HR. In this review, we focus on current and emerging approaches for identifying and targeting HR-deficient EOCs, and discuss the challenges associated with these approaches.
- Published
- 2017
- Full Text
- View/download PDF